Fosnetupitant (Arokaris)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist.

History of changes in PMDA indication

  • 2022-03-28: Newly indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.).

Also known as

  • Generic name: fosanetupitant chloride hydrochloride
  • Brand name: Arokaris